Ann: Appendix 4C - quarterly, page-5

Looks like it mainly you and I here for now, Silvah. It never ceases to amaze me how the market is either hot or cold on biotech stocks.
I noticed from co website we were recently featured on GenomeWeb after ECCMID, so that might have created a bit of the recent turnover.
I also noticed in 2015 Annual report it says sales revenue is recorded when a distributor contracts for product, so perhaps it takes a while for cash to come in (ie distributor must sell and receive money from customer). Intriguing that the gap is large for this quarter, I wonder if this means OS sales. I wouldn't have thought they require a distributor within Australia.
I also looked more closely at results of STI study. Our kit in basic format picks up chlamydia serovar LGV in addition to garden variety chlam (as well as gonorrhoea) t. Other widely used chlam kits don't specifically detect LGV (they do usually detect gonorrhea as well), rather a specific LGV kit must be used and its not in use by many labs. This means our kit has an extra prong, which should come in handy, since apparently LGV is increasing in incidence. The second panel of our STI kit picks up Mycoplasma which is also increasing and not widely tested for, even though, according to the results of the study, it is reasonably common.